{"ModuleTitle": "Company Description", "CompanyName": "Enanta Pharmaceuticals, Inc.", "Symbol": "ENTA", "Address": "500 ARSENAL STREET, WATERTOWN, Massachusetts, 02472, United States of America", "Phone": "617 607 0800", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biotechnology company that uses our robust, chemistry-driven approach\r\nand drug discovery capabilities to create small molecule drugs primarily for the\r\ntreatment of viral infections and liver diseases. We discovered glecaprevir, the\r\nsecond protease inhibitor discovered and developed through our collaboration\r\nwith AbbVie for the treatment of chronic hepatitis C virus, or HCV. Glecaprevir\r\nis co-formulated as part of AbbVie's leading direct-acting antiviral (DAA)\r\ncombination treatment for HCV, which is marketed under the tradenames MAVYRET\u00ae\r\n(U.S.) and MAVIRET(TM) (ex-U.S.) (glecaprevir/pibrentasvir).&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2019%2f11%2f27%2f0001564590-19-044729.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jay R. Luly", "title": "President, Chief Executive Officer & Director"}, {"name": "Nathalie Adda", "title": "Chief Medical Officer & Senior Vice President"}, {"name": "Paul J. Mellett", "title": "CFO, Principal Accounting Officer & SVP-Finance"}, {"name": "Yat Sun Or", "title": "CSO, Senior Vice President-Research & Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}